Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
复制标题
DOI：
10.1186/1471-2474-11-223
复制
发表时间：
2010-09-28
影响因子：
2.3
通讯作者：
Song YW
中科院分区：
文献类型：
--
作者：
Kang EH;Nakashima R;Mimori T;Kim J;Lee YJ;Lee EB;Song YW
目的：探讨韩国患者肌炎自身抗体与炎症性肌炎临床亚群的关系。采用典型多发性肌炎（PM） （n = 11）和皮肌炎（DM） （n = 38）患者的血清进行免疫沉淀，这些患者符合Bohan和Peter确定炎症性肌炎的标准。一组明确的肌炎自身抗体被调查，以调查每个自身抗体和炎症性肌炎临床亚群之间的关系。63.3%（31/49）的研究对象检测到msa、抗p140或抗p155/140抗体。抗140- kda多肽（抗p140）（18.4%, 9/49）和抗155/140- kda多肽（抗p155/140）（16.3%, 8/49）抗体最为常见，其次是抗mi2（14.3%, 7/49）、抗ars（12.2%, 6/49）和抗srp（2.0%, 1/49）抗体。所有msa与抗p140和抗p155/140抗体互斥。抗p140抗体（23.7%,9/38）、抗p155/140抗体（21.1%,8/38）和抗mi2抗体（18.4%,3/38）仅在DM患者中发现。抗p140抗体与快速进展性间质性肺疾病（ILD）相关（p = 0.001），在DM患者中敏感性为100.0%(4/4)，特异性为85.3%（29/34）。抗p155/140抗体与肿瘤相关性DM相关（p = 0.009），敏感性为55.6%(5/9)，特异性为89.7%（26/29）。当抗p155/140抗体存在时，癌症相关生存期明显差（19.2±7.6 vs 65.0±3.5个月，p = 0.032）。最后，抗ars抗体与PM和DM患者稳定或缓慢进展的ILD相关（p = 0.005）。抗p140和抗p155/140抗体是韩国炎症性肌炎患者常见的自身抗体。尽管研究对象中缺乏临床淀粉样病变DM患者，但抗p140抗体与快速进展的ILD之间存在很强的相关性。抗p155/140抗体与癌症相关性肌炎和不良生存率相关。
To investigate the association between myositis autoantibodies and clinical subsets of inflammatory myositis in Korean patients. Immunoprecipitation was performed using the sera of classic polymyositis (PM) (n = 11) and dermatomyositis (DM) (n = 38) patients who met the Bohan and Peter criteria for definite inflammatory myositis. A panel of defined myositis autoantibodies was surveyed to investigate the association between each autoantibody and clinical subsets of inflammatory myositis. Either MSAs, anti-p140, or anti-p155/140 antibodies were found in 63.3% (31/49) of the study subjects. Anti-140-kDa-polypeptide (anti-p140) (18.4%, 9/49) and anti-155/140-kDa polypeptide (anti-p155/140) (16.3%, 8/49) antibodies were the most common, followed by anti-Mi2 (14.3%, 7/49), anti-ARS (12.2%, 6/49) and anti-SRP (2.0%, 1/49) antibodies. All MSAs and anti-p140 and anti-p155/140 antibodies were mutually exclusive. Anti-p140 (23.7%, 9/38), anti-p155/140 (21.1%, 8/38), and anti-Mi2 (18.4%, 3/38) antibodies were found exclusively in DM patients. Anti-p140 antibody was associated with rapidly progressive interstitial lung disease (ILD) (p = 0.001), with a sensitivity of 100.0% (4/4) and a specificity of 85.3% (29/34) in DM patients. Anti-p155/140 antibody was associated with cancer-associated DM (p = 0.009), with a sensitivity of 55.6% (5/9) and a specificity of 89.7% (26/29). Cancer-associated survival was significantly worse when anti-p155/140 antibody was present (19.2 ± 7.6 vs. 65.0 ± 3.5 months, p = 0.032). Finally, anti-ARS antibodies were associated with stable or slowly progressive ILD in PM and DM patients (p = 0.005). Anti-p140 and anti-p155/140 antibodies were commonly found autoantibodies in Korean patients with inflammatory myositis. Despite the lack of clinically amyopathic DM patients in the study subjects, a strong association was observed between anti-p140 antibody and rapidly progressive ILD. Anti-p155/140 antibody was associated with cancer-associated myositis and poor survival.
登录
查看更多内容
DOI：
10.1016/0190-9622(91)70153-s
发表时间：
1991-06-01
影响因子：
13.8
作者：
EUWER, RL;SONTHEIMER, RD
通讯作者：
SONTHEIMER, RD
影响因子：
5.5
作者：
Kaji, K.;Fujimoto, M.;Takehara, K.
通讯作者：
Takehara, K.
DOI：
10.1002/art.10794
发表时间：
2002-12-15
期刊：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子：
--
作者：
Marie, I;Hachulla, E;Courtois, H
通讯作者：
Courtois, H
影响因子：
4.9
作者：
Chinoy, H;Salway, F;Cooper, RG
通讯作者：
Cooper, RG
影响因子：
5.5
作者：
Kang, EH;Lee, EB;Song, YW
通讯作者：
Song, YW